GeneDx Holdings Corp. Operating Income

Quick Answer

GeneDx Holdings Corp. reported Operating Income of -$13.08 million for fiscal year 2025.

GeneDx Holdings Corp. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$13.08M +43.7%
2024 -$23.21M +87.1%
2023 -$180.60M +73.0%
2022 -$667.65M -49.6%
2021 -$446.15M -84.4%
2020 -$241.99M -695.7%
2019 -$30.41M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$3.25M +58.2% -136.3%
June 30, 2025 $8.96M +184.7% +296.9%
March 31, 2025 -$4.55M +66.7% +41.5%
September 30, 2024 -$7.78M +81.9% +26.5%
June 30, 2024 -$10.58M +79.5% +22.6%
March 31, 2024 -$13.66M +77.4% +68.2%
September 30, 2023 -$42.97M +52.7% +16.8%
June 30, 2023 -$51.62M +68.3% +14.5%
  • GeneDx Holdings Corp. showed an increase of +43.7% in Operating Income compared to the prior fiscal year.
  • Over the 2019–2025 period, GeneDx Holdings Corp.’s operating income has grown by 57.0% (from -$30.41 million to -$13.08 million).
  • The most recent figure is from GeneDx Holdings Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment